U
PRTK

UBS’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

UBS’s Portfolio PRTK Stock Details PRTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-533
Closed -$20K – 10861
2013
Q3 		$20K Buy
533
+200
+60% +$7.16K ﹤0.01% 8072
2013
Q2 		$12K Buy
+333
New +$14.3K ﹤0.01% 8460

Other funds holding PRTK

RAM
Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
SKK
Shepherd Kaplan Krochuk Boston, Massachusetts $119M AUM 8.32% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

UBS's PRTK Position: Q3 2014 in Review

UBS increased its Paratek Pharmaceuticals, Inc. (PRTK) stake by 5.7% in Q3 2014, buying an estimated $1.33K and bringing the position to 951 shares worth $23K. The position accounts for ﹤0.01% of the portfolio, ranked #7835.

UBS first reported a position in PRTK in Q2 2013 and has held it in 6 quarters since. The position peaked at $46K in Q1 2014. 36 funds tracked by Wall St. Rank hold PRTK as of Q3 2014.

  • UBS held 951 shares of Paratek Pharmaceuticals, Inc. worth $23K as of Q3 2014.
  • UBS bought 51 Paratek Pharmaceuticals, Inc. shares in Q3 2014, an estimated $1.33K.
  • Paratek Pharmaceuticals, Inc. made up ﹤0.01% of UBS's portfolio in Q3 2014, its #7835 holding.
  • UBS first reported a position in Paratek Pharmaceuticals, Inc. in Q2 2013 and has held it in 6 quarters since.
  • UBS's Paratek Pharmaceuticals, Inc. position peaked at $46K in Q1 2014.
  • 36 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.